Protagonist Therapeutics
Presence
Protagonist Therapeutics is one of the...
Protagonist Therapeutics is a company listed under the stock ticker PTGX (US).
Executives
View the org chart displaying its 19 main executives
Most searched biographies at Protagonist Therapeutics
- Dinesh Patel, Director, President and Chief Executive Officer
- Lewis Williams, Director
- Bryan Giraudo, Director
Popular executive movements at Protagonist Therapeutics
- Daniel Swisher has joined the company as Director (posted on October 31 2023).
Create your alert
to follow the executive moves at Protagonist Therapeutics.
Biotechnology
Protagonist Therapeutics has 2,282 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
- Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
- Histogen has filed for bankruptcy protection (posted on April 19 2024).
Popular contacts in Biotechnology
News
Press releases by Protagonist Therapeutics
- Protagonist Therapeutics Receives Orphan Drug Designation from the European Medicines Agency for PTG-300 in Polycythemia Vera | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the Jefferies Next Generation IBD Therapeutics Virtual Summit 2020 | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Reports Granting of Inducement Award | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Host PTG-300 Opportunity Update Webinar | Protagonist Therapeutics, Inc.
- Protagonist Appoints Sarah O'Dowd to Board of Directors | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update | Protagonist Therapeutics, Inc.
- Hepcidin Mimetic PTG-300 Receives U.S. FDA Orphan Drug Designation for the Treatment of Polycythemia Vera | Protagonist Therapeutics, Inc.
- Press Releases | Protagonist Therapeutics, Inc.
- Protagonist Therapeutics to Participate in the BMO Prescriptions for Success Healthcare Conference | Protagonist Therapeutics, Inc.
- View more press releases Close
Social media about Protagonist Therapeutics
- Protagonist Therapeutics on Wikipedia, Google News & Yahoo Finance
- Protagonist Therapeutics on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Sarah O'Dowd 
Call Protagonist Therapeutics at +1 408...
